{"version":"1.0","provider_name":"ARC Oxford","provider_url":"https:\/\/www.arcgroup.io\/oxford","author_name":"nataliegelder","author_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/nataliegelder\/","title":"OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease - ARC Oxford","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"wNJ6yzyId0\"><a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/\">OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/09\/09\/omass-therapeutics-partners-with-genentech\/embed\/#?secret=wNJ6yzyId0\" width=\"600\" height=\"338\" title=\"&#8220;OMass Therapeutics\u00a0 partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease&#8221; &#8212; ARC Oxford\" data-secret=\"wNJ6yzyId0\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.arcgroup.io\/oxford\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/09\/OMass-Therapeutics-partners-with-Genentech.png","thumbnail_width":1731,"thumbnail_height":607,"description":"ARC Oxford based OMass Therapeutics has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialise OMass' preclinical oral small molecule program for inflammatory bowel disease."}